Abstract
Background The novel coronavirus (SARS-CoV-2) pandemic is driving many countries to adopt global isolation measures in an attempt to slow-down its spread. These extreme measures are associated with extraordinary economic costs.
Objective To compare the cost-effectiveness of global isolation of the whole population to focused isolation of individuals at high risk of being exposed, augmented by thorough PCR testing.
Design We applied a modified Susceptible, Exposed, Infectious, Removed (SEIR) model to compare two different strategies in controlling the SARS-CoV-2 spread.
Data sources and target population We modeled the dynamics in Israel, a small country with ∼ 9 million people.
Time horizon 200 days.
Interventions 1. Global isolation of the whole population (strategy 1) 2. Focused isolation of people at high risk of exposure with extensive PCR testing (strategy 2).
Outcome measures Number of deaths and the cost per one avoided death in strategy 1 vs 2.
Results of Base-Case analysis The number of expected deaths is 389 in strategy 1versus 432 in strategy 2. The incremental cost-effectiveness ratio (ICER) in case of adhering to global isolation will be $ 102,383,282 to prevent one case of death.
Results of sensitivity analysis The ICER value is between $ 22.5 million to over $280 million per one avoided death.
Conclusions According to our model, global isolation will save ∼43 more lives compared to a strategy of focused isolation and extensive screening. This benefit is implicated in tremendous costs that might result in overwhelming economic effects.
Limitations Compartment models do not necessarily fit to countries with heterogeneous populations. In addition, we rely on current published parameters that might not reliably reflect infection dynamics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available within the article or its supplementary materials
